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Background: Tumors are diseases characterized by uncontrolled cell growth and, in spite of the progress of
medicine over the years, continue to represent a major threat to the health, requiring new therapies. Several
synthetic compounds, such as those derived from natural sources, have been identified as anticancer drugs; among
these compounds quinone represent the second largest class of anticancer agents in use. Several studies have
shown that these act on tumor cells through several mechanisms. An important objective of this work is to
develop quinoidscompounds showing antitumor activity, but with fewer side effects. The parachinone cannabinol
HU-331, is a small molecule that with its core 4-hydroxy-1,4-benzoquinone, exhibits a potent and selective cytotoxic
activity on different tumor cell lines. A series of derivatives 3-hydroxy-1,4-benzochinoni were thus developed
through HU-331 chemical modifications. The purpose of the work is to test the ability of the compounds to induce
proliferative inhibition and study the mechanisms of cell death.
Methods: The antitumor activities were evaluated in vitro by examining their cytotoxic effects against different
human cancer cell lines. All cell lines tested were plated in 96-multiwell and treated with HU-100-V at different
concentrations and cell viability was evaluated byMTT assay. Subsequently via flow cytometry (FACS) it was possible
to assess apoptosis by the system of double labeling with PI and Annexin-V, and the effect of the compounds on
ROS formation by measuring the dichlorofluorescein fluorescence.
Results: The substitution by n-hexyl chain considerably enhanced the bioactivity of the compounds. In details,
2-hexyl-5-hydroxycyclohexa-2,5-diene-1,4-dione (V), 2,5-Dimethoxy-3-hexyl-2,5-cyclohexadiene-1,4-dione (XII) and
2-hydroxy-5-methoxy-3-hexyl-cyclohexa-2,5-diene-1,4-dione (XIII) showed most prominent cytotoxicity against
almost human tumour cell lines. Compound V was further subjected to downstream apoptotic analysis,
demostrating a time-dependent pro-apoptotic activity on human melanoma M14 cell line mediated by caspases
activation and poly-(ADP-ribose)-polymerase (PARP) protein cleavage.
Conclusions: These findings indicate that 2-hexyl-5-idrossicicloesa-2,5-diene-1,4-dione can be a promising
compound for the design of a new class of antineoplastic derivatives.
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Several benzoquinones have been found to be effective
in the treatment of some forms of cancer; previous stud-
ies demonstrated that these drugs act on cells by numer-
ous mechanisms, such as apoptosis, abrogation of the
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reproduction in any medium, provided the orproduction of reactive oxygen species (ROS), inhibition
of topoisomerases I and II, activation of intracellular sec-
ond messengers, and production of free radicals to at-
tack DNA. However, their cumulative heart toxicity
limits their use1; therefore, an important goal of present
and future work is to develop quinoid compounds that
display anticancer activity but with less side effects.
Among the 1,4 benzoquinones, there are several natur-
ally occurring quinones having potent anticancer activity.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Development of compounds of general formula A and B.
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http://www.jeccr.com/content/32/1/24A recent work [1] demonstrated that Ardisianone,
a natural benzoquinone derivative, displayed anti-
proliferative and apoptotic activities against human
hormone-refractory prostate cancer cells (HRPC), PC-3,
and DU-145. Previous investigations also showed that
Primin isolated from the leaves of Miconia Lepidota
present in Suriname forests, exhibited activity towards
mutant yeast strains, indicative of their cytotoxicity and
potential antitumor activity [2]. Furthermore Kaul and co-
workers isolated a known cytotoxic quinine Irisoquin
which demonstrated cytotoxic properties [3]. In previous
reports Muhammad et al. [4] evaluated cytotoxic and
antioxidant activities of alkylated benzoquinones from
the leaves of Maesa Lanceolata. Moreover, another
important 2,5-dihydroxy-3-alkyl-1,4-benzoquinone is
Embelin known for a very long time in Indian and
Chinese pharmacopoeias. It is the major constituent
in the extracts of various parts of the shrub Embelia
Ribes. Embelin and its derivatives possess analgesic,
anti-inflammatory, antioxidant, antitumor and antifer-
tility properties [5-7].
Important results have been described with HU-331,
that exhibited potent and selective cytotoxicity against
several tumorigenic cell lines such as Burkitt’s lymph-
oma, glioblastoma, breast, prostate and lung cancer
[8]. Recent findings described that this derivative is
strongly antiangiogenic at concentration as low as 300
nM by directly inducing apoptosis of vascular endothe-
lial cells [9-11].
As a part of our research program devoted to the
preparation and evaluation of new antiproliferative
agents, [12-14] the para-quinone of cannabinol HU-331
(1) was selected as biologically validated starting point
for compound library development, in order to evaluate
the structural requirements important for biological ac-
tivity and in particular the role of the substituents linked
to the quinone nucleus.
We prepared compounds analogues whose structure
closely resembles the natural compound, thus the
2-hydroxy 1,4 benzoquinone core was not changed.
Methods
Chemistry
Compounds I-V (series I) retain the same hydroxy-1,
4-benzoquinone core of lead, modifications were carried
out on the alkyl chain that was elongated and shifted,
cycloalkenyl substituent in position 2 of HU-331 was re-
moved (compound V) or replaced by a cyclohexyl (I and
II) or by a cyclohexylmethyl moiety (III and IV).
On the other hand, to evaluate the influence of position
of alkyl chain and hydroxy group on the 1,4-benzoquinone
nucleus, compounds VI, VII and VIII were prepared. In
parallel, we studied the variation of the cytotoxicity in a
series of 2,5-dihydroxy-3-alkyl-1,4-benzoquinone system(series II). These compounds (IX- XIV) are characterized
by a butyl or hexyl chain in position 3 of quinone ring
which is 2,5 disubstituted with hydroxy or methoxy groups
(Figure 1).
Compounds I and II were prepared starting from
commercially available 1,3-dimethoxybenzene (2a) and
1-hexyl-2,4-dimethoxybenzene (2b) that were easily pre-
pared according to procedure described by Kikuchi and
co-workers [12-14]. Condensation of cyclohexanone
with 2a-b gave the tertiary alcohols 3a-b in 70% and 80%
yields respectively.
In order to remove their hydroxyl groups, 3a-b were
submitted to the Barton-McCombie procedure, an ex-
tremely useful method with widespread application in
synthetic organic chemistry. Compounds obtained were
oxidized into quinoid compounds I (65% yield) and II
(60% yield). Deprotection and final oxidation in air
under basic conditions, led to the formation of the
desired quinones III and IV in 55% and 60% yield,
respectively.
The choice of the effective oxidizing agent and condi-
tions used in the last step of both the synthetic schemes,
derived from a set of experiments applied to the oxida-
tion of the commercially available model compound
4-hexylresorcinol 10 to V, as shown in Table 1.
For example the conversion of 10 to V was tried in the
presence of Salcomine, a coordination complex derived
from the salen ligand and cobalt.
This catalyst is known to catalyze the oxidation of 2,6-
disubstituted phenols by dioxygen but in our case a
complete conversion of the starting material 10 in o-
hydroxyquinone was observed (Entry 1–2).
In another attempt, using a catalytic amount of etha-
nol in air, a solution of 5% of KOH as base and
Table 1 Oxidation of 4-Hexylresorcinol to V with different
oxidizing agents
Entry Conditions Yield (%)
1 Salcomine (0.01 eq.) ,DMF, 110°C, 3 h 30a
2 Salcomine (1 eq.), DMF, rt, 6 h 50a
3 Etanol/air, Petroleum ether, KOH 5%, 0°C, 5 h 33
4 Fremy’s salt, Aliquat336/Ph, Na2CO3, rt, 18 h 30
a
5 Fremy’s salt, H2O, Na2HPO4, rt to 50°C, 36 h 22
6 Fremy’s salt, H2O/EtOAc, Na2HPO4, 0°C to rt, 18 h 50
7 Fremy’s salt, H2O/THF, Na2CO3,rt, 10 h 60
aConversion of starting material in o-hydroxyquinone.
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tity of starting material was converted into quinone V.
For these reasons Fremy’s salt (disodium nitrosodi-
sulfonate) was tried as oxidizing agent, under several
conditions (Entry 4–7). However, in the presence of
Na2CO3 as base and a mixture of H2O/THF as solvent,
was obtained the best results (Entry 7) [15].
Ag(I)-promoted Suzuki–Miyaura cross-coupling of 1-
bromo-2,3.5-trimethoxybenzene (11) and hexylboronic
acid pinacol ester furnished intermediate 12 in 20% yield.
Deprotection and simultaneous oxidation to 2-hydroxy-p-
benzoquinone (VI) was achieved treating 12 with an excess
of BBr3. Oxidation with ammonium cerium nitrate (CAN)
in a mixture of acetonitrile and water allowed to obtain
2-methoxy derivative VII. Compound VIII was synthesized
starting from 1,3-dimethoxybenzene (2a) which was
subjected to a ortho-metalation reaction in presence of n-
BuLi. Coupling reaction of 1,2,4,5-tetramethoxybenzene
with two different alkyl iodides, in presence of n-BuLi and
hexamethylphosphoramide (HMPA) furnished intermedi-
ates 15 and 16 in moderate yields (42% and 37% respect-
ively). CAN-mediated oxidative reaction provided22a
mixture of 2,5-dimethoxy (IX and XII) and 2-hydroxy-5-
methoxy derivatives (X and XIII)
Treatment of IX and XII with 2M NaOH allowed to
obtain 2,5-dihydroxy derivatives XI and XIV in good
yields (72% and 89%).
General procedures
All reagents were analytical grade and purchased from
Sigma-Aldrich (Milano-Italy). Flash chromatography was
performed on Carlo Erba silica gel 60 (230÷400 mesh;
Carlo Erba, Milan, Italy). TLC was carried out using
plates coated with silica gel 60F 254 nm purchased from
Merck (Darmstadt, Germany). Melting points were de-
termined in open capillary tubes on a Electrothermal
9100. 1H and 13C NMR spectra were registered on a
Bruker AC 300. Chemical shifts are reported in ppm. All
target compounds were assessed for purity by analyticalhigh performance liquid chromatography (HPLC), using
an Agilent 1100 series, UV detector monitoring at
254 nm, HP Chem Station software, and a Waters C18
RP-column (5 μm, 300 mm × 3.9 mm). All target com-
pounds were found to be >95% purity. MS spectrometry
analysis ESI-MS was carried out on a Finnigan LCQ
Decaion trap instrument. Microanalyses were carried out
on Carlo Erba 1106 elemental analyzer.
Biological studies
Cell culture
Our experimental models consist of several cell lines
derived from human cancers of different histogenesis.
The cells were grown in RPMI or DMEM supple-
mented with heat inactivated 10% FBS, 20 mM
HEPES, 100 U/ml penicillin, 100 μg/ml streptomycin,
1% L-glutamine in a humidified atmosphere of 95%
air/5% CO2 at 37°C [16].
Analysis of cell proliferation was performed in the
presence of all derivatives on all cell lines seeded in 96-
well plates at the different densities depending on the
cell type. Pancreas cancer cell lines ( BXPC3, PANC-1)
were plated to the average density of 3,600 cells/ well.
Prostate cancer cell lines (DU145, PC3, LNCAP) were
plated to the average density of 2,000 cells/ well. Melan-
oma cell lines (COLO38, A375, M14) were plated to the
average density of 1,800 cells/ well. Renal cancer cell
lines (A498, RXF393, SN12C, 769P) and glioblastoma
cell lines ( LN229, U87 MG, U373 MG) were plated to
the average density of 1,900 cells/ well. Breast cancer cell
lines (CG5, MCF-7, MDA-MB 231, MDA-MB 468,
MDA-MB 436 ) were plated to the average density of
3,100 cells/ well. After 24 h incubation at 37°C, the cells
were treated with increasing concentrations of com-
pounds (0,037-50 μM). Cells were incubated under these
conditions for 72 h.
MTT bioassay
Human cancer cells (3 × 103) were plated in 96-well cul-
ture plates in 90 μL of culture medium and incubated at
37°C in humidified atmosphere of 5% CO2. The day
after, 10 μL aliquot of serial dilutions of compounds
(1–50 μM) was added to the cells and incubated for
72 h. The cell viability was assessed with MTT [3-(4,
5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium brom-
ide] method [17]. After 72 h of treatment with deriva-
tives MTT solution 5 mg/ml in PBS was added to each
well. The plates were then incubated at 37°C for an add-
itional 4 h to allow MTT to form formazan crystals by
reacting with metabolically active cells. The formazan
crystals were solubilized in a 1N isopropanol/HCl 10%
solution at 37°C, on a shaking table for 20 min. The ab-
sorbance values of the solution in each well were mea-
sured at 570 nm using a micro plate reader.
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absorbance of the negative control wells−absorbance of the blank control wellsð Þ  100%as previously reported [18]. All MTT experiments were
performed in quadruplicated and repeated at least three
times. Data are as mean ± standard deviation (SD). Each
IC50 mean value was obtained from four independent
experiments.
Apoptotic cell death
Hypodiploid DNA was analysed using the method of
propidium iodide (PI) staining and flow cytometry as de-
scribed [19]. At the end of incubation with HU com-
pounds, with or without pretreatment with pan-caspase
inhibitor Z-vad-fmk, purchased from BD Pharmingen
(BD Bioscience, Bedford, USA), cells were washed in
phosphate-buffered saline (PBS) and resuspended in 500 μL
of a solution containing 0.1% sodium citrate, 0.1% Tri-
ton X-100 and 50 μg/ml propidium iodide (Sigma-
Aldrich, Italy). After incubation at 4°C for 30 minutes in
the dark, cell nuclei were analyzed with Becton Dickinson
FACScan flow cytometer using the Cells Quest pro-
gram. Cellular debris was excluded from analysis by
raising the forward scatter threshold, and the DNA con-
tent of the nuclei was registered on logarithmic scale.
The percentage of the cells in the hypodiploid region
was calculated [20].
Western blotting analysis
Total intracellular proteins were extracted from the cells
by membrane disruption in lysis buffer 50 mM Tris-
HCl, 1% Na-deoxycholate, 1% SDS and 0.5% IGEPAL
(All from Sigma-Aldrich, Gallarate, Italy) containing pro-
tease and phosphatase inhibitors (1mM PMSF, 1 μg/ml
leupeptin, 1μg/mL pepstatin, 1μg/mL aprotinin, 1 μM
Na3PO4, 1 μM NaF; all from Sigma Sigma-Aldrich,
Gallarate, Italy) on ice for 20 min. The cell lysate was
then centrifugated at 10,000 × g at 4°C for 15 min. The
supernatant was collected as protein extract. Protein
content was estimated according to Biorad protein assay
(BIO-RAD, Milan, Italy) and the samples either analysed
immediately or stored at −80°C. Total protein (30 μg)
samples were loaded into a 10-12% acrylamide gels and
separated by SDS-PAGE in denaturating conditions
at 150 V.
The separated proteins were then transferred electro-
phoretically (100 mA per blot 90 min; Trans Blot Semi-
Dry, BIO-RAD) to nitrocellulose paper (Immobilon-NC,
Millipore, Bedford, USA) soaked in transfer buffer
(25 mM Tris, 192 mM glycine, Sigma-Aldrich) and 20%
methanol vol/vol (Carlo Erba, Milan, Italy) [21]. Nonspecific binding was blocked by incubation of the blots
in 5% no fat dry-milk powder (BIO-RAD) in TBS/0.1%
Tween (25 mM Tris; 150 mM NaCl; 0.1% Tween vol/
vol, Sigma-Aldrich) for 60 min. After washing, the blots
were incubated overnight at 4°C with the following pri-
mary antibodies: mouse monoclonal anti-PARP? (diluted
1:1,000) and anti-XIAP (all from Santa-Cruz Biotechnol-
ogy, Santa Cruz,CA). After incubation with the primary
antibodies and washing in TBS/0.1% Tween, the appropri-
ate secondary antibody, either anti-mouse (diluted 1:5,000),
or anti-rabbit (diluted 1:5,000) (both from Sigma-Aldrich,
Italy) was added for 1h at room temperature. Immunoreac-
tive protein bands were detected by chemiluminescence
using enhanced chemiluminescence reagents (ECL) and
exposed to Hyperfilm (both from Amersham Biosciences,
Italy). The blots were then scanned and analysed (Gel-Doc
2000, BIO-RAD).
Flow cytometric estimation of intracellular redox state
The effect of all compounds on intracellular reactive oxy-
gen species (ROS) was evaluated by measuring
dichlorofluorescein (DCF) fluorescence [22]. Cells were
incubated in presence and absence of compounds. At
the end of incubation time, cells were washed and
resuspended (2 × 105 cells/ml) in Hank’s balanced salt
solution (HBSS) cointaining 10 μM 2′,7′-dichlorodihy-
drofluorescein diacetate (DCFH-DA). Following a further
20 min incubation at 37°C, DCF fluorescence was moni-
tored by flow cytometry (FL1-H channel). In order to esti-
mate the antioxidant potential of the compounds, control
and teatred cells were exposed to 300 μM of the oxidant
tert-bytylhydroperoxide (t-BOOH) for 30 min at 37°C be-
fore DCFH-DA loading.
Topoisomerase I-Mediated DNA cleavage reactions
Human recombinant Top1 was purified from Baculovirus
as previously described [23]. DNA cleavage reactions were
performed using a 22-bp DNA oligonucleotide with a
prominent Topoisomerase I cleavage site. Single-stranded
oligonucleotide was labeled according to the manufac-
turers’ instructions by using terminal deoxynucleo-
tidyltransferase (USB Corporation, Cleveland, OHIO) that
adds a single labeled cordycepin molecule (γ-32P, 5000 Ci/
mmol, PerkinElmer Life and Analytical Sciences, MA) to
the 3′ terminus. Unincorporated nucleotides were re-
moved by QIAquick Nucleotide Removal Kit (Qiagen,
Hilden, Germany). The duplex DNA oligonucleotide was
annealed by addition of an equal concentration of the
Petronzi et al. Journal of Experimental & Clinical Cancer Research 2013, 32:24 Page 5 of 11
http://www.jeccr.com/content/32/1/24complementary strand, heated to 95°C and slow cooled to
room temperature. For the Toposomerase I cleavage reac-
tion, DNA oligonucleotides were reacted for 20 min at
25°C with a 12 ng/mL solution of human Topoisomerase
I and the desired amount of drugs, in 10 mM Tris–HCl
pH 7.5, 50 mM KCl, 5 mM MgCl2, 0.1 mM EDTA and
15 μg/mL bovine serum albumin. Reactions were stopped
by adding 0.5% SDS and formamide containing 0.25%
bromophenol blue and xylene cyanol, heated at 95°C for
5 min and chilled on ice. Reaction products were sepa-
rated in 20% polyacrylamide denaturing sequencing gels.
Dried gels were visualized using a B40 Storm phosphor
imager (Amersham Biosciences, GE Healthcare, UK).
Topoisomerase II-Mediated DNA cleavage reactions
DNA was purchased from Invitrogen Corporation
(Carlsbad, CA). It represents a portion of SV40 sequence,
in particular from position 3449 to 3538, that contains
prominent topoisomerase II cleavage sites [24]. DNA was
purified on denaturing 20% polyacrylamide gel, recovered
by soaking gel slices in water and then ethanol precipi-
tated. Single-stranded DNA was 5′-labeled using T4 poly-
nucleotide kinase (New England Biolabs, Ipswich, MA)
with [γ-32P]ATP (3000 μCi/mmol, PerkinElmer Life and
Analytical Sciences, MA) according to the manufacturers’
instructions. Unincorporated nucleotides were removed
by QIAquick Nucleotide Removal Kit (Qiagen, Hilden,
Germany). The duplex DNA was annealed by addition of
an equal concentration of the complementary strand,
heating to 95°C and slow cooling to room temperature.
For the topoisomerase II cleavage reaction, DNA frag-
ments were reacted for 30 min at 37°C with 30 units/sam-
ple of human topoisomerase II, purified as previously
described, [25] and the desired amount of drugs, in 40 mM
Tris–HCl, pH 7.5, 80 mMKCl, 10 mM MgCl2, 5 mM
DTT, 1 mM ATP, and 15 μg/mL bovine serum albumin.
Reactions were stopped by adding 1% SDS and 0.2 mg/mL
proteinase K and incubated at 42°C for 45 minutes. Sam-
ples were then ethanol precipitated, resuspended in 10 μL
of formamide containing 0.25% bromophenol blue and xy-
lene cyanol, heated at 95°C for minutes and chilled on ice.
Reaction products were separated in 20% polyacrylamide
denaturing sequencing gels. Dried gels were visualized
using a B40 Storm phosphor imager (Amersham Biosci-
ences, GE Healthcare, UK).
Statistical analysis
All results are shown as mean ± SEM of three experi-
ments performed in triplicate. The optical density of the
protein bands detected by Western blotting was normal-
ized on β-actin levels. Statistical comparison between
groups were made using ANOVA followed by
Bonferroni parametric test. Differences were considered
significant if P < 0.05.Results and discussion
Biological evaluation
For the evaluation of cytotoxicity, five different human can-
cer cell lines were utilized: M14 and A375 (melanoma cell
lines), MCF-7 (human breast cancer cell), PC3 (human
prostatecancer cell line), A498 (human renal carcer cell line).
The survival percentage was determined after a period of
72 h at screening concentrations from 50 to 1 μM, using the
survival percentage obtained from the cells treated only with
the solvent (DMSO at 0.5%) as a reference. Our experiments
confirmed the cytotoxic activity of HU-331. Most of the
compounds displayed moderate cytotoxicity against cancer
cell lines in relatively lower micromolar concentrations
when compared to the standard. Among the compounds,
derivatives V, IX, XII and XIII showed significant cytotox-
icity in most of the cell lines, displaying similar or slightly
weaker potency than positive control. Compound V can be
considered the most interesting compound that showed a
good anticancer activity against all tumor cell lines and was
more potent than HU-331 against M14 (7 μM vs 15 μM).
The structure-activity relationship studies regarding the first
series of compounds revealed that the n-hexyl chain in pos-
ition 5 of the hydroxy-quinone ring was fundamental for the
anticancer activity (compounds II, IV and V), in fact com-
pounds I and III, which lacked of the alkyl chain, were com-
pletely inactive. At the same time, the change of position of
alkyl chain was clearly detrimental (VI, VII and VIII vs V).
No relevant influence on the activity was observed if a
methylene spacer was inserted between cyclohexyl and 1,4-
benzoquinone ring (IV vs II). As concern for compounds of
series II, the 5-methoxy-1,4-benzoquinone derivatives IX,XII
and XIII were the most active compounds of the series,
while compound X was slightly active only against M14 cell
line. Considering the importance of the length of the side
chain, the hexyl chain seemed to be more favorable for the
activity but further investigations will be done. 2,5-
dihydroxy-1,4-benzoquinone derivatives XI and XIV were
completely inactive against all tumor cell lines at the con-
centration of 100 μM. Structure-activity relationship evalua-
tions, comparing compounds of first and second series,
demonstrated that the introduction of a methoxy (XII) or
hydroxy (XIII) group on the 1,4-benzoquinone ring of com-
pound VII caused a strong improvement in the cytotoxicity
against almost tumor cell lines, except A498. On the con-
trary, if another hydroxy group was inserted on the quinone
core of compound VI, no improvement of activity was
recorded (compound XIV). Having identified, from the first
screening, the most cytotoxic compound against all tumor
cell lines, we have carried out a screening on other solid
tumor cell lines to confirm the cytotoxic activity of this mol-
ecule. Moreover, we investigated the molecular mechanisms
underlying the antiproliferative activity in comparison with
the natural compound HU-331 on M14 cells. How-
ever all data are reported in Table 2. The MTT
Table 3 Cytotoxic activity of compound V in solid human
cancer cell lines















Table 2 Effects of HU compounds on proliferation of several cancer cell lines
Cell lines IC50 [μM]
Cpd R1 R2 R3 R4 M14 MCF-7 PC3 A498 A375
I H H H >100 >100 >100 >100 >100
II n-hexyl H H 23 ± 0.12 28.13 ± 0.07 41 ± 0.20 34.91 ± 3.82 >100
III H H H >100 >100 >100 >100 >100
IV n-hexyl H H 45.6 ± 0.20 37.3 ± 0.34 38 ± 0.12 28.8 ± 0.04 30.7 ± 0.12
V n-hexyl H H H 7.0 ± 0.10 18.7 ± 0.06 24.3 ± 0.20 19.8 ± 0.02 12.9 ± 0.06
VI H n-hexyl H H - >100 >100 >100 >100
VII H n-hexyl CH3 H - >100 >100 >100 >100
VIII H H CH3 n-hexyl - >100 >100 >100 >100
IX -CH3 n-butyl CH3 H 24.5 ± 0.15 12 ± 0.03 17.9 ± 0.20 51 ± 0.02 17.6 ± 0.05
X H n-butyl CH3 H 35 ± 0.64 >100 >100 >100 >100
XI H n-butyl H H >100 >100 >100 >100 >100
XII -CH3 n-hexyl CH3 H 10.7 ± 0.15 16.2 ± 0.03 18.8 ± 0.03 >100 21.0 ± 0.04
XIII H n-hexyl CH3 H 14.1 ± 0.15 13.9 ± 0.04 20.1 ± 0.20 >100 18.1 ± 0.04
XIV H n-hexyl H H >100 >100 >100 >100 >100
H331 15.0 ± 0.09 24.5 ± 0.15 32.0 ± 0.15 34.6 ± 0.23 21.8 ± 0.03
Cell viability was assessed through MTT assay. Data represent the mean ± SD values of three independent determinations performed in triplicate.
A375, M14, human melanoma cells; MCF-7, human breast cancer cells; PC3, Human prostate cancer cell line, A498, Human renal cancer cell line.
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antiproliferative properties against all tested solid
human cancer cell lines (Table 3).
In vitro cytotoxicity
The cytotoxicity of HU-100-V was evaluated on different
cell lines derived from different tumors. In all treatments
the cells were plated in 96-multiwell in the presence of
increasing concentrations of the drug, (0,37 to 50 μM).
The MTT viability assay showed that HU 100-V de-
creased the viability of most of the cell lines tested in a
time- and dose-dependent manner for which they are
achieved good values of IC50 (concentration inhibiting
50% of growth). Especially, prostate cancer DU-145, pan-
creas cancer BX-PC3 [26,27], renal cancer RXF393 and
glioblastoma cancer LN229 cells have proved to be the
most sensitive to this treatment, with IC50 values of less
than 20 micromolar (Table 3 and Figure 2).
Apoptotic cell death
To ascertain whether loss of cell viability was mediated
by effects on apoptosis we directly analyzed the effects
Figure 2 Dose–response curves from the treatment of different cell lines with the molecule HU-100-V with an IC50 between more less
than 20 μM.
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using PI-staining of DNA fragmentation after cell
permeabilization. Cells were treated with different con-
centrations (1–10 μM) of V and HU-331 for 24 and
72 hours and then the population of sub-G1 cells
(hyplodiploid nuclei) was determined. Compound V in-
duced apoptosis of M14 cells in a concentration-
dependent manner with 40% of cell death at 10 μM after
72 h, whereas a small pro-apoptotic effect was observed
with 10 μM HU-331 (Figure 3). These results showed
that the cytotoxic effect of V is dependent by an apop-
totic mechanism that is more significant than HU-331
effect on M14 cells.Figure 3 Effects of HU compounds on apoptosis of human
melanoma M14 cells. Analysis of the % of apoptotic cells was
performed using PI cell permeabilization staining. M14 cells were treated
with different concentrations of HU-331 and V (1–10 μM) for 24–72 h.
Cells were then collected and % of hypodiploid nuclei was analyzed by
flow cytometry (*** P < 0.001 vs 72 h control cells; ° P < 0.05, °°° P < 0.001
vs 24 h control cells). Results are expressed as mean ± SEM of three
experiments performed in triplicate.Caspases involvement
To investigate the involvement of caspases in the mech-
anism of apoptosis induced by compounds, we
pretreated the cells with a pan-caspase inhibitor Z-VAD-
fmk for 30 min before to add V and HU-331. Results in
Figure 4 show that apoptosis induced by V in presence
of the inhibitor was significantly reduced indicating the
involvement of caspases in the apoptotic mechanism in
M14 cells.
Cell cycle analyses
The cell cycle is divided into four phases, i.e. sub-G1,
G1, S and G2. The sub-G1 represents the apoptotic cells
whereas the G1 represents the first phase of cell cycle in
which cell prepares itself for DNA synthesis. The cell
cycle assay was performed through tagging the DNA
with the PI dye as explained in “Materials and Methods”.
M14 cells were plated in 6-well tissue culture plates.
The cells were induced with compound V (10 μM) and
the standard HU-331 (10 μM) and analyzed on a
FACScan instrument using CELLQuestPRO software
after time intervals of 24 h and 72 h. Cell cycle phases
were compared in treated and untreated samples. No ef-
fect for either HU-331 or V was observed on cell cycle
distribution of melanoma cells (data not shown).
Intracellular pathway involvement
Evasion from apoptosis is one of the hallmarks of human
cancers contributing to tumor formation and treatment
Figure 4 Effects of the caspase inhibitor Z-VAD-FMK on
apoptosis induced by HU331 and V in human melanoma M14
cells. Z-VAD-FMK (30 μM) was administered 30 min before
incubation with HU-331 and V (10 μM) for 72 h and the % of
apoptotic cell was evaluated by flow cytometry (mean ± SEM of
three experiment performed in triplicate; ***P < 0.001 vs control
cells, §§§ P < 0.001 HU331 vs V treated cells.
Figure 5 Effect of HU compounds on intracellular ROS
generation at early time points in M14 cells. Cells were treated
with V and HU331 for 30 min and then intensity of fluorescence of
positive cells to DCFH-DA was analyzed by flow cytometry (FL-1channel).
Results are representative of three experiments performed in triplicate.
MFI:mean fluorescence intensity.
Petronzi et al. Journal of Experimental & Clinical Cancer Research 2013, 32:24 Page 8 of 11
http://www.jeccr.com/content/32/1/24resistance. The alterations in apoptosis signaling path-
way often occur in drug-resistant cancer cells. In par-
ticular, defective apoptosis signaling may be caused by
an increase in content of anti-apoptotic molecules and/
or by a decreased content or impaired function of pro-
apoptotic proteins. Thus, identification of novel sub-
stances for overcoming the drug resistance has gained
much attention in cancer therapy. The drug resistance
of cancer cells is a complex phenomenon comprising
different intracellular processes. It was described for
doxorubicin that short-term-treated CEM cells gradually
developed drug resistance. In particular, caspases activa-
tion, and XIAP and PARP cleavage were blocked. There-
after, we evaluated the effect of the active apoptotic
concentrations on expression of X-linked Inhibitor of
Apoptosis Protein (XIAP) and Poly (ADP-ribose) poly-
merase (PARP) proteins. Cells were treated with V and
HU-331 at 10 μM for 24 h and then the expression of
XIAP and cleavage of PARP were analyzed by westernblotting. Results in Figure 5 show that apoptotic effect of
V was due to PARP cleavage that leads to inactivation of
this protein, importantly involved in DNA repair. No ef-
fect on PARP cleavage was observed with HU-331 treat-
ment. We also showed (Figure 6) that V was able to
abolish XIAP protein levels whereas a little effect was
observed in reduction of XIAP expression after HU-331
treatment.
ROS involvement
The quinoid anticancer agents undergo enzymatic re-
duction via one or two electrons to give the correspond-
ing semiquinone radical or hydroquinone. Under aerobic
conditions the semiquinone radical anion can give its
extra electron to molecular oxygen to give the parent
quinone and superoxide radical anion. This reaction se-
quence, is known as redox-cycling, and it continues until
the system becomes anaerobic. Both the semiquinone
and the superoxide radical anion can generate the hy-
droxyl radical, which is the cause of DNA strand breaks
[28]. HU-331 induced cell death of human cancer cell
lines is not mediated by reactive oxygen intermediates/
species, as exposure to HU-331 failed to elicit the gener-
ation of reactive oxygen species. To assess the involve-
ment of free radicals in V- mediated cell death we
measured the production of reactive oxygen species
(ROS) after exposure of compound at different times
(5–120 min) by FACS analysis of DCFH-DA fluores-
cence intensity. Treatment with V increased intracellular
ROS levels at early time point after 5 minutes of treat-
ment with maximal effect after 30 min (Figure 5A),
while we can confirm that the effect of HU-331 was very
poor on ROS intracellular production (Figure 5B).
Topoisomerase inhibition
To determine topoI catalytic activity, assays were carried
out with supercoiled pBR322 DNA as the substrate
according to protocol. Camptothecin (CPT) was the
Figure 6 Western blotting analysis of PARP cleavage and XIAP protein expression after incubation with HU-331 and V(10 μM) for 24 hours.
Blots are representative of three different experiments.
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reactions. Test derivatives did not increase DNA cleav-
age levels. Similar results were obtained with Top2.
Mitonafide was the reference compound for Top2-
mediated DNA cleavage reactions. The findings show
that none of the assessed compounds are poisons of hu-
man Top2, thus their cellular effects can likely be due to
a molecular mechanism different from topoisomerase
poisoning (data not shown).
Conclusion
Natural benzoquinone compounds are a rich source for
modern, molecular targeted-specific drug discovery [29].
Over the years, a great amount of efforts have been spent
to isolate individual compounds and screen for anti-
cancer activity. Previous research has demonstrated thatHU-331 in vivo was more active and less toxic than doxo-
rubicin [10,11] and thus represents a promising lead com-
pound for designing a new class of anti-cancer treatments.
The aim of this study was to check the cytotoxicity of
novel synthetic 1,4 benzoquinone compounds. The new
derivatives together with the natural lead were tested
for their anti-proliferative activity against five cancer cell
lines. The general trend on which the design of these
structure is based has proven to be valid in obtaining
new interesting compounds. In particular, 2-hexyl-5-
hydroxycyclohexa-2,5-diene-1,4-dione (V) resulted the
best synthesized compound; therefore, it was further
subjected to downstream apoptotic analysis. Our study
demonstrated a time-dependent pro-apoptotic activity of
compound V. We determined that cell death of M14 in-
duced by V is mediated by caspases activation and poly-
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addition we showed that HU-331 does not elicit the pro-
duction of ROS while apoptosis induced by compound V
could be activated by production of ROS observed after
30 min of treatment in M14 cells. We can suppose that
the quinone structure permits to this compound to act as
electron acceptor of free radicals that may kill cancer cells.
To better define the possible mechanism of action of com-
pounds, we also examined their dose-dependent effect on
topoisomerases, as HU-331 has been proposed to be a
catalytic inhibitor of topoisomerase II. We tested their
ability to directly inhibit topoisomerases in cleavage assays
demonstrating that our derivatives are not able to poison
the nuclear enzymes. To conclude, the analyses of the
present study have revealed that the synthesized quinine V
has the potential to induce apoptosis in M14 cancer cell
line in vitro and it is very important to note that this com-
pound additionally has the ability to inhibit the expression
of the antiapoptotic protein XIAP, a regulatory protein
that suppresses apoptosis cell death by binding the caspase
proteins [30,31]. On the light of interesting pharmaco-
logical results, a more extensive medicinal chemistry pro-
gram has been engaged to consolidate the series and
identify lead candidates for the design of more potent
antitumor agents based on 2-hydroxyquinone skeleton
which in turn should afford a better understanding of bio-
logical mechanisms regulating apoptosis.
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